SEZI.ST
SinkerSenzime AB (publ) · Healthcare · Sweden · $58M cap · $253K/day traded
SEK 3.60 -4.0% · close 12 Nov · scored 13 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 13 Nov 2026, the MoatMap Score for Senzime AB (publ) (SEZI.ST) is 14/100, ranked against 25,000+ stocks in 38 markets (Quality 28, Value 31, Momentum 33, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT SENZIME AB (PUBL)
Read
Senzime AB develops and commercializes patient monitoring systems, specifically focusing on objective neuromuscular monitoring during anesthesia to prevent post-operative complications. The company's competitive moat is established by its proprietary TetraGraph system, which is backed by clinical validation and a high-margin disposable sensor business model. It operates as a fast-growing niche leader in the global patient safety and medical device market.
FINANCIAL SUMMARY (SEK)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.0M | 35.8M | 58.5M | 104.0M | 95.0% | 107.0M | 114.9M | 184.8M | 33.3% |
| EPS (SEK) | -0.90 | -1.45 | -0.97 | -0.93 | — | -0.62 | — | — | — |
| Shares | 157.2M | 119.7M | 133.2M | 157.2M | 0.0% | 157.2M | — | — | — |
| Debt | 13.0M | 11.5M | 22.7M | 14.0M | 2.4% | 21.1M | — | — | — |
| Equity | 261.9M | 375.5M | 345.9M | 304.5M | 5.1% | — | — | — | — |
| Op CF | -136.8M | -113.9M | -105.9M | -109.1M | — | -71.1M | — | — | — |
| Inv CF | -5.0M | -7.8M | -20.3M | -18.1M | — | — | — | — | — |
| Fin CF | 92.4M | 246.5M | 75.9M | 100.8M | — | — | — | — | — |
No new 52-week low for 6 weeks, 53% above that low, but not back above a rising 50-day average.
Swung more than 74% of stocks we rank over the past year (volatility 60% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor (this stock): It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SEZI.ST are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| SEZI.ST | Senzime AB (publ)(you) | $58M | 14 |
| EPIS-B.ST | Episurf Medical AB (publ) | $100M | 10 |
| BACTI-B.ST | Bactiguard Holding AB (publ) | $56M | 31 |
| DVYSR.ST | Devyser Diagnostics AB (publ) | $87M | 28 |
| SEDANA.ST | Sedana Medical AB (publ) | $97M | 31 |
| BICO.ST | BICO Group AB (publ) | $171M | 33 |
| CRAD-B.ST | C-Rad AB (publ) | $70M | 69 |
| PAX.ST | Paxman AB (publ) | $150M | 56 |
| XVIVO.ST | Xvivo Perfusion AB (publ) | $654M | 36 |
| VITR.ST | Vitrolife AB (publ) | $1.5B | 50 |
Peer medians: ROE 5.4% · P/E 34.1x · Gross margin 68.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.